WuXi Biologics’ partner, TaiMed Biologics, has received approval from the U.S. FDA for Trogarzo (ibalizumab) for the treatment of adult patients living with HIV who have tried multiple HIV medications in the past and whose HIV infections cannot be successfully treated with other currently available therapies.   Fewer than 10 global CDMOs have so far obtained approval from the U.S. FDA for biological products. Trogarzo’s approval makes WuXi Biologics among the world’s top 10, ...